Ovid Therapeutics (OVID) Proxy filing summary

Executive summary

• Annual meeting scheduled for June 10, 2026, with virtual participation available to shareholders.

• Shareholders are encouraged to review proxy materials and vote by June 9, 2026.

Voting matters and shareholder proposals

• Election of Jeremy M. Levin, DPhil, MB BChir, as Class III director is up for vote.

• Advisory vote on executive compensation for named executive officers is included.

• Ratification of KPMG LLP as independent registered public accounting firm for fiscal year ending December 31, 2026.

• Board recommends voting in favor of all proposals.

Board of directors and corporate governance

• Board has nominated Jeremy M. Levin for election as Class III director.